Relapse remains a major cause of treatment failure following allogeneic hematopoietic stem cell transplant (HSCT) for patients with AML or myelodysplastic syndrome (MDS).
Relapse remains a major cause of treatment failure following allogeneic hematopoietic stem cell transplant (HSCT) for patients with AML or myelodysplastic syndrome (MDS). 1 Attempts at salvage following relapse include withdrawal of immunosuppression, chemotherapy, hypomethylating agents, donor lymphocyte infusions (DLIs) and a second HSCT. 2 Success rates are variable and no standard of care exists.
GvHD is an important limiting factor for further treatment following relapse. Given the low incidence of GvHD with T-cell depleted (TCD)-HSCT, 3, 4 we postulated that our patient population represents an important model for potential trial eligibility. We conducted a single-center retrospective analysis of patients who had disease recurrence following their TCD-HSCT for AML or MDS between January 2003 and November 2011 at Memorial Sloan Kettering Cancer Center (MSKCC; New York, NY, USA) to determine their hypothetical eligibility for post-HSCT relapse management trials from clinicaltrails.gov. This review was performed under a waiver of authorization approved by the Institutional Review Board of MSKCC.
Forty of the 255 recipients of TCD-HSCT for AML or MDS relapsed. All 40 patients had received a myeloablative conditioning regimen for their initial transplant. The conditioning regimens included: TBI, thiotepa and fludarabine (n = 5); TBI, thiotepa and cyclophosphamide (n = 9); busulfan, melphalan and fludarabine (n = 25); and one with clofarabine, melphalan and thiotepa. In two patients, bone marrow grafts were TCD by sequential soybean lectin agglutination and sheep RBC (sRBC)-rosette depletion. Thirty patients received peripheral blood stem cell grafts that had undergone CD34+ cell selection using the ISOLEX 300i system (Baxter, Deerfield, IL, USA) followed by sRBC-rosette depletion, and eight patients underwent CD34+ cell selection using the CliniMACS CD34 Reagent System (Miltenyi, Bergisch Gladbach, Germany).
Management of relapse was based on patients' medical condition and at the discretion of the treating physician and patients' preference, with the following four groups identified: supportive care (N = 6), chemotherapy only (N = 15), DLI or Wilms' tumor (WT)-1-specific T cells (DLI, N = 8; WT-1, N = 2) and second HSCT (N = 9). All patients in the DLI/WT-1 and the second HSCT groups received additional chemotherapy before subsequent cellular infusions. Two patients in the second HSCT group also received DLI. Ten patients were treated with hypomethylating agents in the chemotherapy-only group.
Characteristics of patients in the four groups were compared using Fisher's exact test, when categorical, and the Kruskal-Wallis test, when continuous. Overall survival (OS) time was calculated from the date of relapse post HSCT to the date of death. Patients who were still alive were censored at their last follow-up date. Kaplan-Meier methods were used to estimate survival probabilities. Because of the small sample size, a permutation-based logrank test was used to evaluate the differences in OS between groups. Univariable analysis for CR-1 at the time of first HSCT, age ⩾ 60 years old, Karnofsky performance status (KPS) ⩾ 80%, ⩾ 27% blasts at relapse and relapse beyond 5 months after initial HSCT was performed based on published results. 5, 6 Statistical significance was defined as P o0.05. Statistical analyses were conducted using SAS v.9.4 software (SAS Institute, Cary, NC, USA) and R version 3.1.1 software (R Core Development Team, Vienna, Austria) including the 'survival' and 'clinfun' packages.
For the hypothetical trial eligibility portion, we identified 11 and selected 5 ongoing or recently completed trials from clinicaltrials. gov: azacitidine alone (NCT00422890), cellular adoptive immunotherapy (NCT00107354), decitabine followed by second HSCT (NCT00002832), DLIs and dendritic cells (NCT00476177), and azacitidine with DLI (NCT00795548). Trials were selected on the basis of eligibility criteria and usage of different modalities ranging from hypomethylating agents alone to intensive chemotherapy, cellular therapies and a second HSCT for relapse management. The major determinants of trial eligibility were age, KPS, hepatic and renal function, presence of GvHD and sepsis at the time of relapse. None of these trials were randomized comparisons and none were available at MSKCC. Patient's records were reviewed for trial eligibility based on inclusion and exclusion criteria associated with each trial listed on clinicaltrials.gov.
Thirty-two patients were transplanted for AML and eight for MDS. Twenty-eight (70%) of the 40 patients underwent their first TCD-HSCT on a clinical trial at MSKCC. Upon relapse following the initial transplant, seven patients were treated on a clinical trial: four received a second transplant, two received WT-1-specific T cells and one received chemotherapy on clinical trial followed by DLI. Ten patients received DLI (n = 7) or second transplant (n = 3) off protocol. In the 40 total patients, the median follow-up time from relapse among survivors was 7.5 months (range, 4.2-16.4 months). During follow-up, 33 patients died of progressive disease, 1 of GvHD and 1 of progressive neurological disorder. Five patients were alive at the time of analysis: two in the second HSCT group and three in the DLI/WT-1 group. Median OS for all groups was 5.0 months (95% confidence interval, 3.8-11.7). OS differed significantly by treatment group (P o 0.001; Figure 1 ). Median OS (95% confidence interval) was 1.1, 4.4, 11.7 and Months after relapse Overall survival probability
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12.6 months among the supportive care, chemotherapy only, second HSCT and DLI/WT-1 groups, respectively. At 12 months post relapse, the OS probability (95% confidence interval) was 0, 6.7% (1.0, 4.4%), 41.7% (18.5, 94.0%) and 63.0% (36.3, 100%) among the supportive care, chemotherapy only, second HSCT and DLI/WT-1 groups, respectively. Univariable analysis did not show statistically significant improvement in OS for patients who were in CR at the time of first TCD-HSCT (P = 0.967), ⩾ 60 years old (P = 0.249), KPS ⩾ 80% (P = 0.152) or ⩾ 27% blasts at relapse (P = 0.501). Patients who relapsed beyond 5 months after initial TCD-HSCT had an improved OS post relapse (median 9.9 months vs median 2.7 months; P = 0.001). CR was achieved at any time post relapse in one patient in the DLI/WT-1 group and three patients treated with a second HSCT. Of those patients, two remained in remission at the time of analysis, one in the DLI/ WT-1 group and one in the second HSCT group. The analysis of whether achievement of CR correlated with outcomes was not possible owing to the small number of events. Table 1 summarizes the eligibility and exclusion criteria of the five selected trials. Three of the 40 patients would not have been eligible for any of these trials due to GvHD (N = 1) and sepsis (N = 2). Overall, 37/40 (92.5%) of patients were hypothetically eligible for at least one trial. Fifty percent of the patients were eligible for three or four trials. The most common reason for ineligibility was percentage of blasts or myelosuppression in 36 patients (90%) for pre-emptive azacitidine (NCT00422890), lack of available matched related donor in 29 (72.5%) for adoptive cellular therapy (NCT00107354) and age 460 in 15 (37.5%) for decitabine plus second HSCT trial (NCT00002832).
Like other studies, [7] [8] [9] [10] [11] [12] [13] [14] [15] we observed an improved OS in patients who underwent a second HSCT and DLI/WT-1 as compared with patients who received supportive care or chemotherapy only. The only statistically significant factor affecting OS post relapse was time to relapse 45 months. Based on the standard factors determining trial eligibility such as KPS, renal/hepatic function, GvHD and presence of sepsis, 92.5% of our patients were eligible for at least one trial, with 54% eligible for three to four trials. Furthermore, at relapse, 88% of our patients had KPS ⩾ 80%, 76% had a normal kidney and liver function, and 95% were free of uncontrollable infections. Although our patients would have qualified for a variety of trials, in actuality only seven were enrolled to trials primarily to undergo a second HSCT or receive cellular therapy. The low level of enrollment in clinical trial, while partly due to patients' medical condition, was also possibly owing to the unavailability of such trials at our center. This emphasizes the importance of opening and encouraging enrollment on clinical trials for patients with post-transplant relapse. Interestingly, of the 37 patients in this study who would have been ineligible for the pre-emptive azacitidine trial (NCT00422890), 16 received hypomethylating agents. This suggests that perhaps the eligibility criteria in some trials could be broadened.
The small number of patients, lack of a uniform management of relapse and the retrospective nature of this single-center study are its important limitations. Despite these, our study shows the majority of patients to be potential candidates for enrollment on a clinical trial, given the low incidence of GvHD, preserved organ function and good KPS, and provides insight into the impact of an intensive treatment in the post-transplant relapse setting. As we move forward in our understanding of relapse following HSCT, it is essential that we provide patients with the possibility of trial enrollment and long-term disease-free survival.
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